WPD Pharmaceuticals Inc.
WBIO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.48% | -71.78% | -83.30% | -90.18% | -- |
| Depreciation & Amortization | 12.50% | -21.62% | -56.49% | -74.87% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.50% | -71.47% | -83.22% | -90.19% | -- |
| Operating Income | -22.50% | 71.47% | 83.22% | 90.19% | -- |
| Income Before Tax | -100.14% | -102.80% | -104.71% | -102.21% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.14% | -102.80% | -104.71% | -102.21% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.14% | -102.80% | -104.71% | -102.21% | -- |
| EBIT | -22.50% | 71.47% | 83.22% | 90.19% | -- |
| EBITDA | -24.79% | 71.60% | 83.53% | 90.56% | -- |
| EPS Basic | -100.17% | -102.81% | -104.73% | -102.21% | -- |
| Normalized Basic EPS | -127.07% | -174.53% | -111.40% | 63.10% | -- |
| EPS Diluted | -100.17% | -102.81% | -104.73% | -102.21% | -- |
| Normalized Diluted EPS | -127.07% | -174.53% | -111.40% | 63.10% | -- |
| Average Basic Shares Outstanding | 0.57% | 0.08% | 0.00% | 0.00% | -- |
| Average Diluted Shares Outstanding | 0.57% | 0.08% | 0.00% | 0.00% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
